Reply to Y. Inagaki et al.

Abu-Sbeih, Hamzah; Faleck, David M; Dougan, Michael; Wang, Yinghong

Abu-Sbeih, Hamzah; Faleck, David M; Dougan, Michael; Wang, Yinghong.

Afiliação

Abu-Sbeih H; Hamzah Abu-Sbeih, MD, Department of Internal Medicine, The University of Missouri-Kansas City, Kansas City, MO; David M. Faleck, MD, Gastroenterology, Hepatology and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY; Michael Dougan, MD, PhD, Department of Medicine, Division of
Faleck DM; Hamzah Abu-Sbeih, MD, Department of Internal Medicine, The University of Missouri-Kansas City, Kansas City, MO; David M. Faleck, MD, Gastroenterology, Hepatology and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY; Michael Dougan, MD, PhD, Department of Medicine, Division of
Dougan M; Hamzah Abu-Sbeih, MD, Department of Internal Medicine, The University of Missouri-Kansas City, Kansas City, MO; David M. Faleck, MD, Gastroenterology, Hepatology and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY; Michael Dougan, MD, PhD, Department of Medicine, Division of
Wang Y; Hamzah Abu-Sbeih, MD, Department of Internal Medicine, The University of Missouri-Kansas City, Kansas City, MO; David M. Faleck, MD, Gastroenterology, Hepatology and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY; Michael Dougan, MD, PhD, Department of Medicine, Division of

J Clin Oncol ; 38(15): 1749-1750, 2020 05 20.

Article em En | MEDLINE | ID: mdl-32250720

Assuntos

Inibidores de Checkpoint Imunológico; Doenças Inflamatórias Intestinais; Humanos; Radioimunoterapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Inibidores de Checkpoint Imunológico Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google